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Research in autophagy continues to accelerate,1 and as a 
result many new scientists are entering the field. Accordingly, 
it is important to establish a standard set of criteria for moni-
toring macroautophagy in different organisms. Recent reviews 
have described the range of assays that have been used for this 
purpose.2,3 There are many useful and convenient methods 
that can be used to monitor macroautophagy in yeast, but rela-
tively few in other model systems, and there is much confusion 
regarding acceptable methods to measure macroautophagy in 
higher eukaryotes. A key point that needs to be emphasized is 
that there is a difference between measurements that monitor the 
numbers of autophagosomes versus those that measure flux through 
the autophagy pathway; thus, a block in macroautophagy that 
results in autophagosome accumulation needs to be differentiated 
from fully functional autophagy that includes delivery to, and 
*Correspondence to: Daniel J. Klionsky; University of Michigan; Life Sciences 
Institute; Rm. 6036; 210 Washtenaw Ave.; Ann Arbor, Michigan 48109-2216 USA; 
Tel.: 734.615.6556; Fax: 734.763.6492; Email: klionsky@umich.edu
Submitted: 11/21/07; Accepted: 11/21/07
Previously published online as an Autophagy E-publication: 
www.landesbioscience.com/journals/autophagy/article/5338
degradation within, lysosomes (in most higher eukaryotes) or the 
vacuole (in plants and fungi). Here, we present a set of guidelines 
for the selection and interpretation of the methods that can be used 
by investigators who are attempting to examine macroautophagy 
and related processes, as well as by reviewers who need to provide 
realistic and reasonable critiques of papers that investigate these 
processes. This set of guidelines is not meant to be a formulaic 
set of rules, because the appropriate assays depend in part on the 
question being asked and the system being used. In addition, we 
emphasize that no individual assay is guaranteed to be the most 
appropriate one in every situation, and we strongly recommend the 
use of multiple assays to verify an autophagic response. 
At the first Keystone Symposium on Autophagy in Health and 
Disease, one of the researchers in the audience, after listening to 
several comments detailing inadequacies in documenting autophagy, 
asked the question “What are the essential criteria for demon-
strating autophagy?” This is a reasonable question, particularly 
considering that each of us may have his/her own opinion regarding 
the answer. Unfortunately, this presents something of a “moving 
target” for researchers who may think they have met those criteria, 
only to find out that the reviewer of their paper has different ideas. 
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Conversely, as a reviewer, it is tiresome to raise the same objec-
tions repeatedly, wondering why researchers have not fulfilled some 
of the basic requirements for establishing the occurrence of an 
autophagic process. In addition, drugs that potentially modulate 
autophagy are increasingly being used in clinical trials, and screens 
are being carried out for new drugs that can modulate autophagy for 
therapeutic purposes. Clearly it is important to determine whether 
these drugs are truly affecting autophagy based on a set of accepted 
criteria. Accordingly, we describe here a basic set of contemporary 
guidelines that can be used by researchers to plan and interpret their 
experiments, by clinicians to decide which avenue of treatment is 
appropriate, and by both authors and reviewers to justify or criticize 
an experimental approach.
Several fundamental points must be kept in mind as we estab-
lish guidelines for the selection of appropriate methods to monitor 
autophagy. Importantly, there are no absolute criteria for determining 
the autophagic status that apply to every situation. This is because 
some assays are inappropriate, problematic or may not work at all in 
particular cells, tissues or organisms.2 In addition, these guidelines 
may evolve as new methodologies are developed and current assays 
of the process are superseded. Nonetheless, it is useful to establish 
guidelines for acceptable assays that can reliably monitor autophagy 
in many experimental systems. It is important to note that in this 
set of guidelines the term “autophagy” generally refers to macroau-
tophagy; other autophagy-related processes are specifically designated 
when appropriate.
An important point is that autophagy is a dynamic, multi-step 
process that can be modulated at several steps, both positively and 
negatively. In this respect, the autophagic pathway is not different 
from other cellular pathways. An accumulation of autophagosomes 
(be they measured by electron microscopy (EM) image analysis, as 
fluorescent GFP-LC3 dots, or as LC3 lipidation on a western blot), 
could, for example, reflect either increased autophagosome forma-
tion due to increases in autophagic activity, or to reduced turnover 
of autophagosomes (Fig. 1). The latter can occur by inhibiting their 
maturation to amphisomes or autolysosomes, which happens if there 
are defects in fusion with endosomes or lysosomes, respectively, 
or following inefficient degradation of the cargo once fusion has 
occurred.4 For the purposes of this review, the autophagic compart-
ments are referred to as the sequestering (preautophagosomal) 
phagophore,5 the autophagosome,6 the amphisome (generated by 
fusion of autophagosomes with endosomes, also referred to as an 
acidic late autophagosome7)8 and the autolysosome (generated by 
fusion of autophagosomes or amphisomes with a lysosome, also 
referred to as an autophagolysosome).6 We note that the use of the 
term “phagophore” in this review has no implied meaning in regard 
to the origin of the autophagosomal membrane. The word “phago-
phore” was originally coined to indicate that the initial sequestering 
structure was morphologically distinct from other organelles.5 Other 
studies, however, suggest specific origins for the autophagosome 
sequestering membrane, most notably the endoplasmic reticulum.9 
Indeed, recent work suggests that the endoplasmic reticulum, and 
more generally membrane flow through the secretory pathway, is 
required for autophagosome formation.10,11 A complete under-
standing of the membrane source(s) for autophagy awaits further 
study and, accordingly, “phagophore” in the context of this review 
refers only to a particular structure.
Studies related to autophagic cell death or, more properly (because 
it is seldom verified that autophagy is the mechanism underlying 
such programmed cell death), autophagy-associated cell death, 
represent another important situation where it becomes necessary to 
distinguish whether the phenotypic defects arise due to the inhibi-
tion versus induction of autophagy. In some cases, this type of death 
is due to reduced autophagic flux, due to inhibition of the fusion 
of autophagosomes with lysosomes or to loss of the degradative 
functions of lysosomes.12 Therefore, the use of autophagy markers 
such as LC3-II needs to be complemented by knowledge of overall 
autophagic flux to permit a correct interpretation of the results. 
In this case, one needs to measure the rate of general autophagic 
protein breakdown, or to arrest the autophagic flux at a given point 
to record the time-dependent accumulation of an organelle, an 
organelle marker, a cargo marker or the entire cargo at the point of 
blockage. Along the same lines, one can follow the time-dependent 
decrease of appropriate markers. In theory, this can be achieved by 
blocking autophagic sequestration at specific steps of the pathway 
(e.g., blocking further induction or nucleation of a new phago-
phore) and by measuring the decrease of markers behind the block 
Figure 1. Schematic model demonstrating the induction of autophago-
some formation when turnover is blocked versus normal autophagic flux. 
(A) Induction results in the initiation of autophagy including the formation of 
the phagophore, the initial sequestering compartment, which expands into an 
autophagosome. A defect in autophagosome turnover due, for example, to a 
block in fusion with lysosomes or disruption of lysosomal functions will result 
in an increased number of autophagosomes. In this scenario, autophagy has 
been induced, but there is no or limited autophagic flux. This is a different 
outcome than the situation shown in (B) where autophagosome formation is 
followed by fusion with lysosomes and degradation of the contents, allowing 
complete flux, or flow, through the entire pathway.
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point. The key issue is to differentiate between the formation versus 
accumulation of autophagosomes by measuring “steady state” levels 
and the rates of autophagic degradation of cellular components. 
Both processes have been used to estimate “autophagy” but unless 
the experiments can relate changes in autophagosome numbers to 
a direct or indirect measurement for autophagic flux (e.g., clearance 
of a substrate as a direct measurement, or changes in LC3-II as an 
indirect measurement), they may be difficult to interpret. A general 
caution regarding the use of the term “steady state” is warranted at 
this point. It should not be assumed that an autophagic system is 
at steady state as this implies that the level of autophagosomes does 
not change with time and the flux through the system is constant. 
Rather, in this review we use the term steady state to refer to measure-
ments that are static in nature.
Autophagic flux refers to the complete process of autophagy 
including the delivery of cargo to lysosomes (via fusion of the 
latter with autophagosomes or amphisomes) and its subsequent 
breakdown and recycling. Thus, increases in the level of phosphati-
dylethanolamine-modified LC3 (LC3-II), or even the appearance of 
autophagosomes are not measures of autophagic flux per se, but can 
reflect the induction of autophagy and/or inhibition of autophago-
some or amphisome clearance. Furthermore, the degradative capacity 
of a cell, which likely varies with cell type, age, transformation and/
or disease, may determine the outcome of autophagy induction.13 
Finally, it is important to note that while formation of LC3-II corre-
lates with the induction of autophagy, we do not know, at present, 
the actual mechanistic relationship between LC3-II formation and 
the rest of the autophagic process. Accordingly, it is essential to 
distinguish between autophagosome or LC3-II accumulation, and 
autophagic flux.
As a final note, we also recommend that authors refrain from 
the use of the expression “percent autophagy” when describing 
experimental results, as in “The cells displayed a 25% increase in 
autophagy.” In contrast, it is appropriate to indicate that a certain 
percentage of cells display punctate GFP-LC3, or that there is a 
particular increase or decrease in the rate of degradation of long-lived 
proteins, as these are the actual measurements being quantified.
Collectively, we propose the following guidelines for measuring 
these various aspects of autophagy in higher eukaryotes:
A. Monitoring Phagophore and Autophagosome Formation  
by Steady State Methods 
The key reason for separating these guidelines into sections on 
steady state versus flux measurements is that the former rely on 
methods that indicate the induction of autophagy, but do not allow 
a determination of whether the process goes to completion. This is 
an important point because incomplete autophagy, which would lead 
to the accumulation of autophagosomes contributes to physiological 
dysfunction. In contrast, complete autophagy will generally exert a 
cytoprotective effect. 
1. Electron microscopy. Autophagy was first detected by electron 
microscopy. The focal degradation of cytoplasmic areas sequestered 
by the phagophore (a specialized type of smooth, ribosome-free 
double membrane), which matures into the prelysosomal autopha-
gosome is the hallmark of autophagy. Therefore, the use of electron 
microscopy is a valid and important method both for the qualita-
tive and quantitative analysis of changes in various autophagic 
structures that sequentially form, the phagophore, autophagosome, 
amphisome and autolysosome (Fig. 1). The maturation from the 
phagophore through the autolysosome is a dynamic and continuous 
process,14 and thus the classification of compartments into discrete 
morphological subsets can be problematic. Fortunately, for many 
biological and pathological situations, examination of both early and 
late autophagic structures yields valuable data regarding the overall 
autophagy/lysosomal status in the cells.13
Cautionary notes: Although EM is one of the most widely used 
methodologies to monitor autophagy, it is also one of the most prob-
lematic and prone to misinterpretation. Due to the large potential for 
sampling artifact, careful selection of appropriate nonbiased methods 
of quantification and morphometric/stereological analyses are essen-
tial.15 For example, it is better to count autophagosome profiles than 
to just score for the presence or absence of autophagosomes in the 
section of a cell, but the preferred method is to quantify autophago-
some volume as the percent of cytoplasmic volume using volumetric 
morphometry/stereology.16 During quantification it is important to 
make sure that every cell profile in the thin section has equal prob-
ability to be included in the counting.
The reliable identification of the autophagosome is a prerequisite 
for a valid analysis. An additional complication, however, is that 
maturation of mammalian autophagosomes involves a transition to 
single-membrane structures (i.e., amphisomes and autolysosomes).17 
Thus, double membranes do not necessarily represent evidence for 
ultrastructural identification of autophagy-related structures, and it 
is important to employ expert analysis to avoid misinterpretation of 
micrographs. Even among experts, there is some disagreement as to 
the characteristics of an authentic autophagosome.18 For example, 
starvation-induced autophagosomes should contain cytoplasm (i.e., 
cytosol and possibly organelles), but autophagosome-related structures 
involved in specific types of autophagy, such as selective peroxisome 
or mitochondria degradation (pexophagy or mitophagy, respectively) 
or targeted degradation of pathogenic microbes (xenophagy), may 
be relatively devoid of cytoplasm. Furthermore, some pathogenic 
microbes express membrane-disrupting factors during infection (e.g., 
phospholipases) that disrupt the normal double-membrane archi-
tecture of autophagosomes.19 It is not even clear if the sequestering 
compartments used for specific organelle degradation or xenophagy 
should be termed autophagosomes or if alternate terms such as 
pexophagosome20 and xenophagosome should be used, even though 
the membrane and mechanisms involved in their formation may be 
identical to those for starvation-induced autophagosomes. It is also 
difficult to determine whether material present within a phagosomal 
structure derives from self-eating, or from a heterophagic process; 
when appropriate, specific analyses can be performed to assess 
the source of the engulfed material. Regardless, it is necessary to 
prove that the sequestered content becomes completely degraded 
within the membrane-bordered space. This is accomplished by 
demonstrating that sequential disintegration of well-recognizable 
sequestered structures (e.g., mitochondria or rough endoplasmic 
reticulum cisternae) proceeds to completion. The fact that the entire 
disintegration process remains focal is evidence for being completely 
bordered by a membrane in three dimensions. Demonstration of the 
presence of lysosomal enzymes in post-fusion autophagic compart-
ments by traditional immunocytochemistry is also feasible. Finally, 
due to the cisternal structure of the endoplasmic reticulum, double 
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membrane-like structures surrounding mitochondria or other organ-
elles are often observed after sectioning, which actually correspond 
to cisternae of the ER coming into and out of the section plane. 
The presence of ribosomes associated with these membranes helps 
distinguish them from the ribosome-free double-membrane of the 
autophagosome.
In case of potential uncertainties, it is desirable to use immuno-
EM with gold-labeling,21,22 using antibodies to cargo proteins (of 
cytosolic origin; in this case the cargo should not be an abundant 
cytosolic protein or the background will be too high, but organelle 
markers work well) and to LC3 to verify the autophagic nature of the 
compartment. The success of this methodology, however, depends 
on the quality of the antibodies and also on the EM preparation and 
fixation procedures required. With immuno-EM, authors should 
provide controls showing that labeling is specific, by demonstrating 
that the signal is clearly above background. In addition, we recom-
mend that statistical information be provided due to the necessity 
of showing only a selective number of sections. Again, we note that 
for quantitative data it is preferable to use proper volumetric analysis 
rather than just counting numbers of sectioned objects. It must be 
kept in mind, however, that even volumetric morphometry/stere-
ology only shows steady state levels, and by itself is not informative 
regarding autophagic flux. On the other hand, quantitative analyses 
indicate that autophagosome volume in many cases does correlate 
with the rates of protein degradation.23-25 
One additional caveat with EM, and to some extent with confocal 
fluorescence microscopy, is that the analysis of single sections of a cell 
can be misleading and may make the identification of autophagic 
structures difficult. One potential compromise is to perform whole 
cell quantification of autophagosomes using fluorescence methods, 
with qualitative verification by EM,26 to show that the changes 
in fluorescent puncta reflect increases in autophagic structures. 
Confocal microscopy and fluorescence microscopy with deconvolu-
tion software (or with much more work, EM) can be used to generate 
multiple/serial sections of the same cell to reduce this concern, but 
this is generally unnecessary because analyzing single sections of 
multiple cells is more practical and provides more information. An 
additional methodology that is worth noting is correlative light and 
electron microscopy, CLEM, which is helpful in confirming that 
fluorescent structures are autophagosomes.27 Finally, although an 
indirect measurement, a comparison of the ratio of autophagosomes 
to autolysosomes by EM can support alterations in autophagy iden-
tified by other procedures.28 In this case it is important to always 
compare samples to the control of the same cell type, as the ratio 
of autophagosome/autolysosome varies in a cell context-dependent 
fashion, depending on their clearance activity. It may also be neces-
sary to distinguish autolysosomes from telolysosomes/late secondary 
lysosomes (the former are actively engaged in degradation, whereas 
the latter have reached an end point in the breakdown of lumenal 
contents; see part B, section 10) because lysosome numbers generally 
increase when autophagy is induced.
2. Atg8/LC3 western blotting and ubiquitin-like protein conju-
gation systems. The Atg8/LC3 protein is a ubiquitin-like protein 
that can be conjugated to phosphatidylethanolamine (PE). In yeast, 
the conjugated form is referred to as Atg8—PE. The mammalian 
homologues of Atg8 constitute a family of proteins, with micro-
tubule-associated protein 1 light chain 3 (LC3) being the most 
relevant for this discussion (this protein is referred to as “Atg8” in 
other systems, but for simplicity we primarily refer to it here as LC3 
to distinguish it from the yeast protein). LC3 is initially synthesized 
in an unprocessed form, proLC3, which is converted into a proteo-
lytically processed form lacking amino acids from the C terminus, 
LC3-I, and is finally modified into the PE-conjugated form, LC3-II 
(Fig. 2). Atg8—PE/LC3-II is the only protein marker that is reliably 
associated with completed autophagosomes, but is also localized to 
phagophores. In yeast, Atg8 amounts increase at least ten-fold when 
autophagy is induced.29 In mammalian cells, however, the total levels 
of LC3 do not necessarily change, as there may be increases in the 
conversion of LC3-I to LC3-II, or a decrease in LC3-II relative to 
LC3-I if degradation of LC3-II via lysosomal turnover is particularly 
rapid. Furthermore, even if the total amount of LC3 does increase, 
the magnitude of the response is generally less than that documented 
in yeast. Western blotting can easily be used to monitor changes in 
LC3 amounts (Fig. 2). Note, however, that LC3-II western blotting 
has not been used successfully in Drosophila melanogaster (Baehrecke 
E, Neufeld T, unpublished results).
Cautionary notes: There are two important caveats when using 
LC3-II to follow autophagy. First, changes in LC3-II amounts 
are tissue- and cell context-dependent.30,31 Indeed, in some cases, 
autophagosome accumulation detected by electron microscopy 
does not correlate well with the amount of LC3-II (Tallóczy Z, de 
Vries RLA, and Sulzer D, and Eskelinen E-L, unpublished results). 
Conversely, a normal level of LC3-II is not sufficient evidence for 
autophagy. For example, homozygous deletion of beclin 1 does 
not prevent the formation of LC3-II in embryonic stem cells even 
though autophagy is defective, whereas deletion of atg5 does result in 
the complete absence of LC3-II (see Fig. 2B and suppl. data in ref. 
32). Thus, it is important to remember that not all of the autophagy-
related proteins are required for Atg8/LC3 processing, including 
lipidation. Vagaries in the detection and amounts of LC3-I versus 
LC3-II present technical problems. For example, LC3-I is very abun-
dant in brain tissue, and the intensity of the LC3-I band may obscure 
detection of LC3-II, unless the polyacrylamide crosslinking density is 
optimized. Conversely, certain cell lines have much less visible LC3-
I compared to LC3-II. In addition, tissues may have asynchronous 
and heterogeneous cell populations, and this may present challenges 
when analyzing LC3 by western blotting. 
Second, caution must be exercised in general when evaluating 
LC3 by western blotting, and appropriate standardization controls 
are necessary. For example, LC3-I may be less sensitive to detection 
by certain anti-LC3 antibodies, and LC3-I is more labile than LC3-II. 
LC3-I is also more sensitive to freezing-thawing and to degradation 
in SDS sample buffer, so fresh samples should be boiled and assessed 
as soon as possible and should not be subjected to repeated freeze-
thaw cycles. Caveats regarding detection of LC3 by western blotting 
have been covered in a recent review,33 but one important suggestion 
noted here is that one should measure levels of LC3-II relative to 
actin and not to that of LC3-I. In addition, Triton X-100 may not 
efficiently solubilize LC3-II.34 Instead, heating in the presence of 1% 
SDS is needed to ensure complete solubilization, which is essential 
for correct interpretation of results from western blotting. Also, the 
utility of measuring LC3-I depends on the cells being analyzed. 
For example, in contrast to cells from peripheral tissues, LC3-I is 
abundant and stable in central nervous system tissue, and here both 
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the ratio of LC3-II to LC3-I and the amount of LC3-II can be used 
to monitor autophagosome formation.35 Finally, LC3 is expressed 
as three isoforms in mammalian cells, LC3A, LC3B and LC3C,36 
which exhibit different tissue distributions, and it may be necessary 
to use different antisera or antibodies that distinguish among these 
isoforms. A point of caution along these lines is that the increase in 
LC3B-II levels, but not in LC3A-II, correlated with elevated levels 
of autophagic vesicles monitored either by electron microscopy or 
rat GFP-LC3 transfection in response to autophagy-inducing stress 
(Corcelle E, Mograbi B, personal communication). This supports the 
important notion that the LC3 isoforms display different functions, 
and we therefore advise anti-LC3B for western blotting and immu-
nofluorescence experiments rather than anti-LC3A. 
One additional point concerns the monitoring of Atg12—Atg5 
conjugation, which has been used in some studies to measure 
autophagy. In some mammalian cells it appears that essentially all 
of the Atg5 and Atg12 proteins exist in the conjugated form and 
the expression levels do not change, at least during short-term 
starvation.37,38 Therefore, monitoring Atg12—Atg5 conjugation 
per se may not be a useful method for following the induction of 
autophagy. It is worth noting, however, that in some cell lines free 
Atg5 can be detected,39 suggesting that the amount of free Atg5 may 
be cell line-dependent. One final parameter that may be considered 
is that the total amount of the Atg12—Atg5 conjugate may increase 
following prolonged starvation as has been observed in hepatocytes 
and fibroblasts (Cuervo AM, personal communication).
Finally, we would like to point out one general issue with regard to 
any assay is that it could introduce some type of stress, for example, 
mechanical stress due to lysis, temperature stress due to heating or 
cooling a sample, or oxidative stress on a microscope slide, which 
could lead to potential artifacts. This point is not intended to limit 
the use of any specific methodology, but rather to point out there are 
no perfect assays. Therefore, it is important to verify that the positive 
(e.g., rapamycin treatment) and negative (e.g., inhibitor treatment) 
controls behave as expected in any assays being utilized.
3. Fluorescence microscopy. LC3B (hereafter referred to as LC3), 
or the protein tagged at its N terminus with a fluorescent protein 
such as GFP, GFP-LC3, has been used to monitor autophagy 
through indirect immunofluorescence (Fig. 3A) or direct fluores-
cence microscopy (Fig. 3B), measured as an increase in punctate 
LC3 or GFP-LC3.40 The detection of GFP-LC3/Atg8 is also useful 
for in vivo studies using transgenic organisms such as Caenorhabditis 
elegans,41 Dictyostelium discoideum,42 Drosophila melanogaster,43,44 
Arabidopsis thaliana45 and mice.30 It is also possible to use anti-LC3 
antibodies for immunocytochemistry or immunohistochemistry,46-
48 procedures that have the advantages of detecting the endogenous 
protein, obviating the need for transfection and transgenesis, as well as 
avoiding potential artifacts resulting from overexpression. Monitoring 
the endogenous protein, however, obviously depends on the ability to 
detect it in the system of interest. If the endogenous amount is below 
the level of detection, the use of an exogenous construct is warranted. 
In this case, it is important to consider the use of stable transformants 
versus transient transfections. Stable transformants may have reduced 
background resulting from the lower protein expression, and there 
is also the advantage of eliminating artifacts resulting from recent 
exposure to transfection reagents. Furthermore, with stable transfor-
mants more cells can be easily analyzed because nearly 100% of the 
Figure 2. LC3-I conversion and LC3-II turnover. (A) HEK293 and HeLa cells 
were cultured in nutrient-rich medium (DMEM containing 10% FCS) or incu-
bated for 4 h in starvation conditions (Krebs-Ringer medium) in the absence 
(-) or presence (+) of E64d and pepstatin at 10 µg/ml each (Inhibitors). Cells 
were then lysed and the proteins resolved by SDS-PAGE. Endogenous LC3 
was detected by immunoblotting. Positions of LC3-I and LC3-II are indicated. 
In the absence of lysosomal protease inhibitors, starvation results in a mod-
est increase (HEK293 cells) or even a decrease (HeLa cells) in the amount 
of LC3-II. The use of inhibitors reveals that this apparent decrease is due to 
lysosome-dependent degradation. This figure was modified from data previ-
ously published in reference 31, and is reproduced by permission of Landes 
Bioscience, copyright 2005. (B) Expression levels of LC3-I and LC3-II during 
starvation. Atg5+/+ (wild-type) and Atg5-/- MEFs were cultured in DMEM 
without amino acids and serum for the indicated times, and then subjected to 
immunoblot analysis using anti-LC3 antibody and anti-tubulin antibody. E64d 
(10 µg/ml) and pepstatin A (10 µg/ml) were added to the medium where 
indicated. Positions of LC3-I and LC3-II are indicated. Similar to the result 
in (A), the inclusion of lysosomal protease inhibitors reveals that the appar-
ent decrease in LC3-II is due to lysosomal degradation as easily seen by 
comparing samples with and without inhibitors at the same time points (the 
overall decrease seen in the presence of inhibitors may reflect decreasing 
effectiveness of the inhibitors over time). Monitoring autophagy by following 
steady state amounts of LC3-II without including inhibitors in the analysis can 
result in an incorrect interpretation that autophagy is not taking place (due 
to the apparent absence of LC3-II). Conversely, if there are high levels of 
LC3-II but there is no change in the presence of inhibitors this may indicate 
that induction has occurred but that the final steps of autophagy are blocked, 
resulting in stabilization of this protein. This figure was modified from data 
previously published in reference 33, and is reproduced by permission of 
Landes Bioscience, copyright 2007.
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population will express tagged LC3. On the other hand, 
one disadvantage of stable transfectants is that the integra-
tion sites cannot always be predicted, and expression levels 
may not be optimal. Furthermore, an important advantage 
of transient transfection is that this approach is better for 
examining the immediate effects of the transfected protein 
on autophagy. In addition, a double transfection can be 
used (e.g., with GFP-LC3 and the protein of interest) to 
visually tag the cells that express the protein being exam-
ined, an approach that may be more problematic with 
stable transfectants. In conclusion, there is no simple rule 
for the use of stable versus transient transfections. When 
stable transfections are utilized, it is worthwhile screening 
for clones that give the best signal to noise ratio, and 
when transient transfections are used, it is worthwhile 
optimizing the GFP-LC3 DNA concentration to give the 
best signal to noise ratio. Optimization, together with 
including the appropriate controls, will help overcome the 
effects of the inherent variability in these analyses. 
An additional use of GFP-LC3 is to monitor co-local-
ization with a target during autophagy-related processes 
such as organelle degradation or the sequestration of 
pathogenic microbes.49-51 For observing autophagy in 
C. elegans, it is best to use an integrated version of 
GFP-LC3 (GFP:LGG-1; Fig. 4) rather than an extra-
chromosomal construct because the latter shows variable 
expression among different animals (Kang C, personal 
communication). In addition, with the integrated version 
it is still possible to perform a western blot analysis for lipi-
dation.52 Finally, we point out the increasing availability 
of instruments that are capable of nanoscale resolution for 
GFP-based microscopy, which will further enhance the 
value and possibilities afforded by this technology.53
Yeast Atg18 is required for both macroautophagy (i.e., 
non-specific sequestration of cytoplasm) and autophagy-
related processes (e.g., the cytoplasm to vacuole targeting 
pathway,54,55 specific organelle degradation,56 and 
autophagic elimination of invasive microbes57-61).62 A 
recent study shows that the human homologue of Atg18 
(WIPI-1) accumulates at LC3-positive membrane struc-
tures when autophagy is induced, and the increase in 
Atg18 puncta correlates with elevated levels of LC3-II.63 
Endogenous levels of Atg18 can also be detected by indirect 
fluorescence microscopy and immunoelectron microscopy, 
and the distribution of transfected GFP-Atg18 appears 
similar. Accordingly, Atg18 puncta can be assessed as an 
alternative to LC3. With regard to other Atg proteins, 
Atg9 also displays partial co-localization with GFP-LC3.64 
Monitoring the localization of Atg9 has not been used 
extensively in higher eukaryotes, but this protein displays 
the same type of dependence for cycling on Atg1/Ulk1 as 
seen in yeast,64,65 suggesting that it is possible to follow 
this protein as an indication of Atg1 function. Finally, 
Atg8/LC3 is the only protein known to remain associ-
ated with the autophagosome in higher eukaryotes, but 
additional proteins, in particular Atg5, Atg12 and Atg16, 
associate with the phagophore and have been detected by 
fluorescence or immunofluorescence.37,38
Figure 3. Changes in the localization of LC3 and GFP-LC3 upon the induction of autoph-
agy. (A) Immunofluorescence in mouse fibroblasts and human T cells. The indicated cells 
were left untreated or were treated with 100 µM rapamycin for 4 h and were subjected 
to immunofluorescence with a selective antibody against LC3. LC3-stained autophagic 
compartments in T cells are indicated with arrows. Quantification of 20 cells similar to 
the ones shown here indicated that rapamycin-treated cells had 165 ± 8 vesicles per 
fibroblast and 6 ± 2 vesicles per T cell. Bar, 5 µm. This figure was previously published 
in reference 2, and is reproduced by permission of Landes Bioscience, copyright 2007. 
(B) Direct fluorescence in stable MEF transformants. GFP-LC3-expressing Atg5+/+ and 
Atg5-/- MEFs were cultured in DMEM with 10% FBS or DMEM without amino acids 
and serum for 1.5 h. Cells were fixed with 3% PFA and analyzed by fluorescence 
microscopy. Bar, 20 µm. This figure was previously published in reference 69, and is 
reproduced by permission of Landes Bioscience, copyright 2007.
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Cautionary notes: Although analysis of fluorescent GFP-LC3 
is a useful approach, it is more tedious to quantify autophagy by 
measuring puncta of GFP-LC3 (or LC3 by immunofluorescence), 
than by monitoring LC3-II by west rn blot. Ideally, it is preferable 
to include both assays and to compare the two sets of results. In addi-
tion, if GFP-LC3 is being quantified, it is preferable to determine 
the number of puncta corresponding to GFP-LC3 on a per cell basis 
rather than simply the total number of cells displaying puncta. This 
latter point is critical because even cells in nutrient-rich conditions 
display some basal level of  GFP-LC3 puncta, unless they are lacking 
autophagy-related genes (and even in the latter case it is possible 
to get puncta of GFP-LC3 depending on the specific conditions) 
(Fig. 3B). There are, however, practical issues with counting puncta 
manually and reliably, especially if there are large numbers per cell 
(although this may be more accurate than relying on a software 
program, in which case it is important to ensure that only appro-
priate dots are being counted). Also, when autophagosome-lysosome 
fusion is blocked, larger autophagosomes are detected, possibly due 
to autophagosome-autophagosome fusion. In many cell types it may 
be possible to establish a cut-off value for the number of puncta 
per cell in conditions of “low” and “high” autophagy.66 This can 
be tested empirically by exposing cells to autophagy-inducing and 
-blocking agents. Thus, cell populations showing significantly greater 
proportions of cells with autophagosome numbers higher than the 
cut-off in perturbation conditions compared to the control cells 
could provide quantitative evidence of altered autophagy. It is then 
possible to score the population as the percentage of cells displaying 
numerous autophagosomes. This approach will only be feasible if the 
background number of puncta is relatively low, and, in this case, it is 
particularly important to count a large number of cells (probably on 
the order of fifty or more, preferably in at least three different trials, 
depending on the particular system and experiment). 
To allow comparisons by other researchers attempting to repeat 
these experiments, it is critical that the authors also specify the 
baseline number of puncta that are used to define “normal” or “low” 
autophagy. Furthermore, the cells should also be counted using 
unbiased procedures (e.g., using a random start point followed by 
inclusion of all cells at regular intervals), and statistical information 
should be provided for both baseline and altered conditions, as these 
assays can be highly variable. One possible method to obtain unbi-
ased counting of GFP-LC3 puncta in a large number of cells is to 
perform multispectral imaging flow cytometry. This method allows 
characterization of single cells within a population by assessing a 
combination of morphology and immunofluorescence patterns, 
thereby providing statistically meaningful data.67 An additional 
caution is that size determinations can be problematic by fluores-
cence microscopy unless careful standardization is carried out.68 
Furthermore, it is not clear that different sizes of GFP-LC3 puncta 
correlate with levels of autophagy.
One possible control to determine background levels of puncta 
is to examine fluorescence from untagged GFP. An important caveat 
in the use of GFP-LC3 is that this chimera can associate with aggre-
gates, especially when expressed at high levels in the presence of 
aggregate-prone proteins, which can lead to a misinterpretation of 
the results.69 Of note, GFP-LC3 can associate with ubiquitinated 
protein aggregates;70 however, this does not occur if the GFP-LC3 
is expressed at low levels (Rubinsztein DC, unpublished observa-
tions). These aggregates have been described in many systems, 
and are also referred to as Aggresome-Like Induced Structures or 
ALIS,70,71 dendritic cell ALIS,72 p62 bodies/sequestosomes73 and 
inclusions. Inhibition of autophagy in vitro and in vivo leads to the 
accumulation of these aggregates, suggesting a role for autophagy 
in mediating their clearance.70,71,74,75 The adaptor protein p62 is 
required for the formation of ubiquitinated protein aggregates in 
vitro.73 In this case, the interaction of p62 with both ubiquitinated 
proteins and LC3 is thought to mediate delivery of these aggregates 
to the autophagy system.76 Many cellular stresses can induce the 
formation of aggregates, including transfection reagents.70 Moreover, 
calcium phosphate transfection of COS7 cells or lipofectamine trans-
fection of MEFs (Pinkas-Kramarski R, personal communication) 
or neuronal cells (Chu CT, personal communication) transiently 
increases basal levels of GFP-LC3 puncta and/or the amount of 
LC3-II. One solution is to examine GFP-LC3 puncta in cells stably 
expressing GFP-LC3; however, as transfection-induced increases in 
GFP-LC3 puncta and LC3-II are often transient, another approach 
is to use cells transfected with GFP, and cells subjected to a mock 
time-matched transfection as background (negative) controls. A 
Figure 4. GFP::LGG-1 is an autophagy marker in C. elegans. GFP::LGG-1 
expression in the hypodermal seam cells of (A) wild-type N2 animals and 
(B) daf-2(e1370) animals that have an increase in autophagy. The arrow 
shows representative GFP-positive punctate areas that label pre-autopha-
gosomal and autophagosomal structures. This figure was modified from 
data previously published in Meléndez A, Tallóczy Z, Seaman M, Eskelinen 
E-L, Hall DH, Levine B. Autophagy genes are essential for dauer develop-
ment and life-span extension in C. elegans. Science 2003; 301:1387-91. 
Reprinted with permission from AAAS.
©
20
08
 L
an
de
s 
Bi
os
ci
en
ce
. D
o 
no
t d
is
tr
ib
ut
e.
Monitoring autophagy in higher eukaryotes
160 Autophagy 2008; Vol. 4 Issue 2
lipidation-defective LC3 mutant where glycine 120 is mutated to 
alanine is targeted to these aggregates independently of autophagy 
(likely via its interaction with p62, see above) and as a result this 
mutant can serve as another valuable control.70 
Ubiquitinated protein aggregate formation and clearance appear 
to represent a cellular recycling process.  Aggregate formation can 
occur when autophagy is either inhibited or when its capacity for 
degradation is exceeded by the formation of proteins delivered to the 
aggregates. In principle, formation of GFP-LC3-positive aggregates 
represents a component of the autophagy process.  However, the 
formation of ubiquitinated GFP-LC3-positive protein aggregates does 
not directly reflect either the induction of autophagy (or autophago-
some formation), or flux through the system. Indeed, formation of 
ubiquitinated protein aggregates can occur in autophagy-deficient 
cells.70 Therefore it should be remembered that GFP-LC3 puncta 
likely represent a mix of ubiquitinated protein aggregates in the 
cytosol, ubiquitinated protein aggregates within autophagosomes 
and more “conventional” phagophores and autophagosomes bearing 
other cytoplasmic cargo. Moreover, a recent report shows that treat-
ment with saponin and other detergents can provoke artifactual 
GFP-LC3 puncta formation.77 Saponin treatment has been used to 
reduce background fluorescence under conditions where no aggrega-
tion of GFP-LC3 is detected in both hepatocytes,78 and in GFP-LC3 
stably-transfected HEK-293 cells (Tooze S, unpublished data); 
however, controls need to be included in such experiments in light of 
these findings. In general, it is preferable to include additional assays 
that measure autophagy rather than relying solely on monitoring 
GFP-LC3. In addition, we recommend that researchers validate 
their assays at the start by demonstrating the absence or reversal of 
GFP-LC3 puncta formation in cells treated with pharmacological 
or RNA interference-based autophagy inhibitors. For example, 
3-methyladenine (3-MA) is commonly used to inhibit starvation- or 
rapamycin-induced autophagy.
Another general limitation of the GFP-LC3 assay is that it 
requires a system amenable to either transfection or transgenesis 
(e.g., infection). Accordingly, the use of GFP-LC3 in primary non-
transgenic cells is more challenging. Here again, controls need to 
be included to verify that the transfection protocol itself does not 
artifactually induce GFP-LC3 puncta or cause LC3 aggregation. 
Furthermore, transfection should be performed with low levels of 
constructs, and the transfected cells followed to determine (1) when 
sufficient expression for detection is achieved, and (2) that during the 
time frame of the assay, basal GFP-LC3 puncta remain appropriately 
low. In addition, the demonstration of a reduction in the number of 
induced GFP-LC3 puncta under conditions of autophagy inhibition 
is helpful. For some primary cells, delivering GFP-LC3 to precursor 
cells by infection with recombinant lentivirus, adenovirus79 or retro-
virus, and subsequent differentiation into the cell type of interest, 
is a powerful alternative to transfection of the already differentiated 
cell type.80 
An additional consideration is that transfection protocols, or 
viral infection, activate stress pathways in some cells and possibly 
induce autophagy, again emphasizing the importance of appropriate 
controls, such as control viruses expressing GFP.78 When carrying 
out transfections it may be necessary to alter the protocol depending 
on the background. In addition, changing the medium and waiting 
24 to 48 hours after the transfection can help to reduce the 
background level of GFP-LC3 puncta that is due to the transfection 
reagent (Colombo MI, personal communication). When using an 
mCherry-GFP-p62 double tag (see below under Tandem RFP-GFP 
fluorescence microscopy) in transient transfections it is best to wait 
48 hours after transfection to reduce the level of aggregate forma-
tion and potential inhibition of autophagy (Johansen T, personal 
communication).
Finally, although LC3-II is primarily membrane associated, 
it is not necessarily associated with autophagosomes as is often 
assumed; the protein is also found on phagophores, the precursors 
to autophagosomes. In addition, the site of LC3 conjugation to 
PE is not known and levels of Atg8—PE/LC3-II can increase even 
in autophagy mutants that cannot form autophagosomes.81 One 
method that can be used to examine LC3-II membrane association 
is differential extraction in Triton X-114, which can be used with 
mammalian cells.79 Another approach is to examine co-localization 
of LC3 with Atg5 (or other Atg proteins); the Atg12—Atg5 conju-
gate does not remain associated with autophagosomes so co-localized 
structures would correspond to phagophores. Importantly, we stress 
again that numbers of GFP-LC3 puncta, similar to steady state LC3-
II levels, reflect only a snapshot of the numbers of autophagy-related 
structures (e.g., autophagosomes) in a cell, and not autophagic flux.
With regard to detection of Atg18 or GFP-Atg18, it has not been 
demonstrated whether Atg18 puncta can be detected in systems 
other than human cells, and the level of puncta formation is cell 
context-dependent.63 Additionally, Atg18 has not been detected on 
the completed (mature) autophagosome, so it may only decorate the 
phagophore. Accordingly, the formation of Atg18 puncta may only 
be useful to monitor autophagy induction and not flux.
4. TOR and Atg1 kinase activity. TOR complex I (TORC1) 
negatively regulates autophagy in a transcription-independent 
manner downstream of protein kinase B. In most systems, inhibition 
of TOR leads to induction of autophagy. TORC1 activity can be 
monitored by following the phosphorylation of its target protein(s) 
or downstream effectors, such as p70S6 kinase or the S6 protein.82,83 
For p70S6 kinase, it is important to examine phosphorylation at 
threonine 389, which is a direct target of TOR and is rapamycin-
sensitive; the C-terminal phosphorylation sites do not always 
correlate with TOR activation (Murphy LO, personal communica-
tion). Accordingly, it is better to quantify p70S6 kinase activity in 
vitro, but this requires greater effort. A decrease in TORC1 activity 
can lead to autophagy induction, however, it is not a direct measure-
ment. In contrast, in vitro Atg1 kinase activity towards an exogenous 
substrate appears to increase when autophagy is induced.84 In yeast, 
and presumably in other organisms, it is possible to measure Atg1 
kinase activity to verify the induction of autophagy.
Cautionary notes: There are TOR-independent mechanisms that 
induce autophagy.85-88 Thus, it is necessary to verify that the pathway 
being analyzed displays TOR-dependent inhibition. At present, 
the use of Atg1 kinase activity as a tool to monitor autophagy is 
limited because an authentic substrate has not been characterized; 
the current assays rely on in vitro phosphorylation of the artificial 
substrate myelin basic protein. When a physiological substrate(s) of 
Atg1 is identified it will be possible to follow its phosphorylation in 
vivo as is done with analyses for TOR.
5. Transcriptional regulation. The induction of autophagy in 
certain scenarios is accompanied by an increase in the mRNA levels 
©
20
08
 L
an
de
s 
Bi
os
ci
en
ce
. D
o 
no
t d
is
tr
ib
ut
e.
Monitoring autophagy in higher eukaryotes
www.landesbioscience.com Autophagy 161
of certain autophagy genes, such as Atg8/LC389 and Atg12.90 Thus, 
assessing the levels of LC3 mRNA by northern blot or qRT-PCR 
may provide correlative data relating to the induction of autophagy. 
It is not clear if these changes are sufficient to induce autophagy, 
however, and therefore these are not direct measurements. Of note, 
large changes in Atg gene transcription just prior to Drosophila mela-
nogaster salivary gland cell death (that is accompanied by an increase 
in autophagy) are detected in Atg2, Atg4, Atg5 and Atg7, whereas 
there is no significant change in Atg8a or Atg8b.91,92 However, tran-
scriptional upregulation of Drosophila melanogaster Atg8a and Atg8b 
is observed in fat bodies following induction of autophagy at the end 
of larval development,93 and an increase in Drosophila melanogaster 
Atg8b is observed in cultured Drosophila melanogaster l(2)mbn cells 
following starvation (Gorski S, personal communication).
Cautionary notes: Most of the Atg genes do not show significant 
changes in mRNA levels when autophagy is induced. Even increases 
in LC3 mRNA can be quite modest and are cell type- and organism-
dependent.94 In addition, it is generally better to follow protein levels 
because that is the ultimate readout that is significant with regard to 
the initiation and completion of autophagy, although Atg protein 
amounts do not always change significantly and the extent of increase 
is again cell type- and tissue-dependent. Finally, changes in autophagy 
protein levels are not sufficient evidence of autophagy induction, and 
must be accompanied by additional assays as described herein.
B. Monitoring Autophagy by Flux Measurements
Autophagy includes not just the increased synthesis or lipidation 
of Atg8/LC3, or an increase in the formation of autophagosomes, 
but most importantly flux, or flow, through the entire system, 
including lysosomes or the vacuole. Therefore, autophagic substrates 
need to be monitored to verify that they have reached this organelle, 
and, when appropriate, degraded.
1. Autophagic protein degradation. Protein degradation assays 
represent a well-established methodology for measuring autophagic 
flux, and they allow good quantification. The general strategy is first 
to label cellular proteins by incorporation of a radioactive amino 
acid (e.g., [14C]-leucine or [14C]-valine), preferably for a long time 
to achieve sufficient labeling of the long-lived proteins that best 
represent autophagic substrates, and then to follow this with a long 
cold-chase so that the assay starts well after labeled short-lived proteins 
are degraded. Next, the time-dependent release of acid-soluble radio-
activity from the labeled protein in intact cells or perfused organs is 
measured.2,95 A considerable fraction of the measured degradation 
will, however, be non-autophagic, and thus one should also measure, 
in parallel, cell samples treated with autophagy-suppressive concen-
trations of 3-MA or amino acids; these values are then subtracted 
from the total. The complementary approach of using compounds 
that block other degradative pathways, such as proteasome inhibi-
tors, may cause unexpected results due to crosstalk among the 
degradative systems. For example, blocking proteasome function 
may activate autophagy.96-98 Thus, when using inhibitors it is critical 
to know whether the inhibitors being used alter autophagy, in the 
particular cell type and context being examined. In addition, because 
3-MA could have some autophagy-independent effects in particular 
settings it is advisable to verify that the 3-MA-sensitive degradation 
is also sensitive to general lysosomal inhibitors (such as ammonium 
chloride or leupeptin). 
Another assay that could be considered relies on the limited 
proteolysis of a betaine homocysteine methyltransferase (BHMT) 
fusion protein. Previous studies show that the 44 kDa full-length 
BHMT protein is cleaved in hepatocytic lysosomes in the presence 
of leupeptin to generate a 32 kDa fragment.99,100 Accumulation 
of the 32 kDa species is time-dependent and is blocked by 
treatment with autophagy inhibitors. A modified version of this 
marker, GST-BHMT, can be expressed in other cell lines where it 
behaves similar to the wild-type protein (Mercer C, Kaliappan A, 
Dennis PB, personal communication). Other substrates may be 
considered for similar types of assays. For example, the neomycin 
phosphotransferase II-GFP (NeoR-GFP) fusion protein is a target 
of autophagy.101 Transfection of lymphoblastoid cells with a plasmid 
encoding NeoR-GFP followed by incubation in the presence of 
3-MA leads to an accumulation of the NeoR-GFP protein as 
measured by flow cytometry.102
Cautionary notes: Measuring the degradation of long-lived 
proteins requires prior radiolabeling of the cells (and subsequent 
separation of acid-soluble from acid-insoluble radioactivity), and 
although the labeling can be done with relative ease in cultured cells, 
such pulse-chase experiments are not possible in animals, although 
they can be done in perfused organs. In cells, it is also possible to 
measure the release of an unlabeled amino acid by chromatographic 
methods, thereby obviating the need for prelabeling.103 In either 
case, one potential problem is that the released amino acid may be 
further metabolized. For example, branched chain amino acids are 
good indicators of proteolysis in hepatocytes, but not in muscle 
cells where they are further oxidized (Meijer AJ, personal commu-
nication). Furthermore, the amino acid can be reincorporated into 
protein; for this reason, such experiments can be carried out in the 
presence of cycloheximide, but this raises additional concerns (see 
Turnover of autophagic compartments below). In the case of labeled 
amino acids, a non-labeled chase is added where the tracer amino 
acid is present in excess (being cautious to avoid using an amino acid 
that inhibits autophagy), or by use of single pass perfused organs 
or superfused cells.104,105 The perfused organ system also allows 
for testing the reversibility of effects on proteolysis and the use of 
autophagy-specific inhibitors in the same experimental preparation, 
which are crucial controls for proper assessment. 
 If the autophagic protein degradation is low (as it will be in cells 
in replete medium), it may be difficult to measure it reliably above 
the relatively high background of non-autophagic degradation. It 
should also be noted that the usual practice of incubating the cells 
under “degradation conditions,” that is, in a saline buffer, indicates 
the potential autophagic capacity (maximal attainable activity) of the 
cells rather than the autophagic activity that prevails in vivo or under 
rich culture conditions. Finally, inhibition of a particular degrada-
tive pathway is typically accompanied by an increase in a separate 
pathway as the cell attempts to compensate for the loss of degrada-
tive capacity.98,106 This compensation might interfere with control 
measurements under conditions that attempt to inhibit macroau-
tophagy; however, as the latter is the major degradative pathway, the 
contributions of other types of degradation over the course of this 
type of experiment are most often negligible.
2. Turnover of LC3-II. Autophagic flux can be measured by infer-
ring LC3-II turnover by western blot (Fig. 2)31 in the presence and 
absence of lysosomal degradation. Preventing lysosomal degradation 
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can be achieved through the use of protease inhibitors (e.g., 
leupeptin and E64d) or drugs such as bafilomycin A1 that 
alter the lysosomal pH,107 or by treatment with agents that 
block fusion of autophagosomes with lysosomes. 
One of the most recent additions to methodologies 
for monitoring autophagy relies on the observation that 
a subpopulation of LC3-II exists in a cytosolic form 
(LC3-IIs) in some cell types.108 The amount of cytosolic 
LC3-IIs and the ratio between LC3-I and LC3-IIs appears 
to correlate with changes in autophagy and provides a more 
accurate measure of autophagic flux than ratios based on 
the total level of LC3-II.108 The validity of this method has 
been demonstrated by comparing autophagic proteolytic 
flux in rat hepatocytes and hepatoma cells. One advantage 
of this approach is that it does not require the presence of 
autophagic or lysosomal inhibitors to block the degrada-
tion of LC3-II. 
Cautionary notes: The main caveat regarding the 
measurement of LC3-IIs/LC3-I is that it is not yet known 
whether this method is generally applicable to other cell types, and 
a soluble form of LC3-II is not observed in many standard cell types 
including HeLa, HEK293 and PC12. In addition, the same concerns 
apply regarding detection of LC3-I by western blotting. It should 
be noted that the LC3-IIs/LC3-I ratio must be analyzed using the 
cytosolic fractions rather than the total homogenates. In addition, 
the same caveats mentioned above regarding the use of LC3 for quali-
tatively monitoring autophagy also apply to the use of this marker 
for following flux. 
The use of a radioactive pulse-chase analysis provides an alter-
native to lysosomal protease inhibitors,29 although such inhibitors 
should still be used to verify that degradation is lysosome-dependent. 
In addition, drugs must be used at concentrations and for time spans 
that are effective in inhibiting fusion or degradation, but that do 
not provoke cell death. Thus, these techniques may not be practical 
in all cell types or in tissues from whole organisms where the use of 
protease inhibitors is problematic, and where pulse labeling requires 
artificial short-term culture conditions that may induce autophagy.
It may not be absolutely necessary to follow LC3-II turnover if 
other substrates are being monitored simultaneously. For example, 
an increase in LC3-II levels in combination with the lysosomal (or 
ideally autophagy-specific) removal of an autophagic substrate (such 
as a polyQ-expanded protein for researchers studying neurodegen-
eration, or an organelle109) that is not a good proteasomal substrate 
provides an independent assessment of autophagic flux. 
3. GFP-Atg8/LC3 lysosomal delivery and proteolysis. GFP-
LC3B (GFP-LC3) has also been used to follow flux. First, when 
GFP-Atg8 or GFP-LC3 is delivered to a lysosome the Atg8/LC3 part 
of the chimera is sensitive to degradation, whereas the GFP protein 
(although not necessarily GFP fluorescence) is relatively resistant to 
hydrolysis. Therefore, the appearance of free GFP on western blots 
can be used to monitor lysis of the inner autophagosome membrane 
and breakdown of the cargo (Fig. 5).110-112 The movement of GFP-
LC3 to lysosomes also can be monitored by fluorescence microscopy, 
although the GFP fluorescent signal is more sensitive to acidic pH 
than other fluorophores. In either case, it can be problematic to use 
GFP fluorescence to follow flux, as new GFP-LC3 is being synthe-
sized. A potential solution to this problem for following fluorescence 
is to use a photoactivatable version of the fluorescent protein,113 
which allows this assay to be performed essentially as a pulse/chase 
analysis. Another alternative is to follow flux using GFP-LC3 fluo-
rescence by adding lysosomal protease inhibitors to cells expressing 
GFP-LC3 and monitoring changes in the number of puncta. In this 
case, the presence of lysosomal inhibitors should increase the number 
of GFP-LC3-positive structures, and the absence of an effect on 
the total number of GFP-LC3 puncta or on the percentage of cells 
displaying numerous puncta is indicative of a defect(s) in autophagic 
flux.114 The combination of protease inhibitors (to prevent the 
degradation of GFP) or compounds that modify lysosomal pH such 
as ammonium chloride or chloroquine, or drugs such as bafilomycin 
A1 along with compounds that block fusion of autophagosomes with 
lysosomes (e.g., vinblastine) may be most effective in preventing lyso-
some-dependent decreases in GFP-LC3 puncta. However, because 
the stability of GFP is affected by lysosomal pH, we advise the use 
of protease inhibitors whether or not lysosomotropic compounds or 
fusion inhibitors are included. Finally, a new method was recently 
developed utilizing the fluorescence activated cell sorter to allow 
quantitative analysis of GFP-LC3 turnover (Shvets E, Fass E, Elazar 
Z, personal communication).
Cautionary notes: The main limitation of the GFP-LC3 processing 
assay is that it seems to depend on cell types and culture conditions 
(Hosokawa N, Mizushima N, unpublished data). Apparently, GFP 
is more sensitive to mammalian lysosomal hydrolases than the degra-
dative milieu of the yeast vacuole. Alternatively, the lower pH of 
lysosomes relative to that of the vacuole may contribute to differences 
in detecting free GFP. Therefore, if this method is used it should be 
accompanied by immunoblotting including controls to address the 
stability of non-lysosomal GFP such as GFP-LC3-I. Along these 
lines, a caution concerning the use of the eGFP fluorescent protein 
for microscopy is that this fluorophore has a relatively neutral pH 
optimum for fluorescence,115 so that its signal may diminish quickly 
at a reduced pH. Thus, it may be preferable to use an alternate fluo-
rophore such as red fluorescent protein (RFP) or mCherry, which 
retain fluorescence even at acidic pH.116 Another alternative to RFP 
or mCherry is to use the Venus variant of YFP, which is brighter than 
mRFP and less sensitive to pH than GFP.117 The pH optimum of 
Figure 5. GFP-LC3 processing can be used to monitor delivery of autophagosomal 
membranes. Atg5-/- MEFs engineered to express Atg5 under the control of the Tet-off 
promoter were grown in the presence of doxycyline (10 ng/ml) for one week to sup-
press autophagy. Cells were then cultured in the absence of drug for the indicated 
times, with or without a final 2 h starvation. Protein lysates were analyzed by western 
blot using anti-LC3 and anti-GFP antibodies. The positions of GFP-LC3-I, GFP-LC3-II and 
free GFP are indicated. This figure was modified from data previously published in 
reference 111, FEBS Letters, 580, Hosokawa N, Hara Y, Mizushima N, Generation of 
cell lines with tetracycline-regulated autophagy and a role for autophagy in controlling 
cell size, pp. 2623–9, copyright 2006, with permission from Elsevier.
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eGFP is important to consider when using GFP-LC3 constructs, as 
the original GFP-LC3 marker40 uses the eGFP variant, which may 
result in a reduced signal upon the formation of amphisomes or 
autolysosomes. An additional caveat when using the photoactivatable 
construct PA-GFP115 is that the process of activation by photons 
may induce DNA damage, which could, in turn, elicit induction of 
autophagy. Finally, GFP is relatively resistant to denaturation, and 
boiling for 5 min may be needed to prevent folded protein from 
being trapped in the stacking gel during SDS-PAGE.
4. p62 western blot. In addition to LC3, it is also possible to use 
p62/SQSTM1 as a marker, at least in certain settings.33 The p62 
protein serves as a link between LC3 and ubiquitinated substrates.118 
p62 becomes incorporated into the completed autophagosome and 
is degraded in autolysosomes (Fig. 6A). A recent study shows that 
inhibition of autophagy correlates with increased levels of p62, 
suggesting that steady state levels of this protein reflect the autophagic 
status.119,120 Interestingly, another report shows that p62 is involved 
in inclusion body formation and that loss of p62 attenuates the liver 
injury that results from a deficiency in autophagy.121 In contrast, loss 
of p62 had little effect on neuronal degeneration, suggesting a cell-
type specific nature to inclusion body-related pathologies.
Cautionary notes: One problem with p62 is that it is presently 
not known if this protein is a general marker for autophagy, although 
it binds strongly to LC3 as well as to ubiquitinated substrates. In 
addition, it is most easily used to assess the down-regulation rather 
than the induction of autophagy (i.e., p62 levels only increase when 
autophagy is blocked; Fig. 6B). For example, there is no obvious 
difference in p62 amounts after 30 minutes of autophagy induc-
tion, whereas a change in LC3-II can be detected by this time.33 
Furthermore, it is necessary to examine endogenous p62 because 
overexpression of this protein leads to the formation of protein 
inclusions. In fact, even endogenous p62 becomes Triton X-100-
insoluble in the presence of protein aggregates and when autophagic 
degradation is inhibited; thus, results with this protein are often 
context-dependent. In addition, p62 participates in proteasomal 
degradation, and its level may also increase when the proteasome 
is inhibited.122 Finally, p62 may be transcriptionally upregulated 
under certain conditions,123 further complicating the interpreta-
tion of results. In conclusion, although analysis of p62 can assist in 
assessing the impairment of autophagy, we do not recommend using 
p62 alone to monitor flux.
5. Autophagic sequestration assays. Autophagic activity can also 
be monitored by the sequestration of autophagic cargo, using either 
an (electro)injected, inert cytosolic marker such as [3H]raffinose,124 
or an endogenous cytosolic protein such as lactate dehydrogenase,125 
in the latter case along with treatment with a proteinase inhibitor 
(e.g., leupeptin) to prevent intralysosomal degradation of the protein 
marker. The assay simply measures the transfer of cargo from the 
soluble (cytosol) to the insoluble (sedimentable) cell fraction (which 
includes autophagic compartments), with no need for a sophisticated 
subcellular fractionation (a filtration assay would presumably work 
just as well as centrifugation, although it would be necessary to verify 
that the filtration membrane does not destroy the integrity of the 
post-nuclear supernatant compartments). The cargo marker can be 
quantified by an enzymatic assay, or by western blotting. In principle, 
any intracellular component can be used as a cargo marker, but cyto-
solic enzymes having low sedimentable backgrounds are preferable. 
Membrane-associated markers are less suitable, and proteins such 
as LC3, which are part of the sequestering system itself, will have a 
much more complex relationship to the autophagic flux than a pure 
cargo marker such as lactate dehydrogenase.
Sequestration assays can be designed to measure flux through 
individual steps of the autophagy pathway. For example, microtubule 
inhibitors such as vinblastine will block autophagosome-lysosome 
fusion, and intralysosomally degraded sequestration probes such 
as [14C]lactate will mark only prelysosomal compartments in cells 
treated with this inhibitor,126 and these have been used to obtain 
background control data for monitoring of the overall autophagic 
pathway (autophagic lactolysis).127 One caveat, however, is that 
some of these inhibitors promote sequestration through an unknown 
mechanism (see Autophagy inhibitors and inducers).
A variation of this approach applicable to mammalian cells 
includes live cell imaging. Autophagy induction is monitored as the 
movement of cargo, such as mitochondria, to GFP-LC3-colocal-
izing compartments, and then fusion/flux is measured by delivery of 
cargo to lysosomal compartments.79,128 In addition, sequestration of 
fluorescently tagged cytosolic proteins into membranous compart-
ments can be measured, as fluorescent puncta become resistant to 
the detergent digitonin.129 
Cautionary notes: The electro-injection of radiolabeled probes 
is technically demanding, but the use of an endogenous cytosolic 
protein probe is very simple and requires no pretreatment of the cells 
other than with a protease inhibitor. Another concern with electro-
injection is that it can affect cellular physiology, so it is necessary to 
verify that the cells behave properly under control situations such 
as amino acid deprivation. An alternate approach for incorporating 
exogenous proteins into mammalian cell cytosol is to use “scrape-
loading,” a method that works for cells that are adherent to tissue 
culture plates.130 Finally, these assays work well with hepatocytes 
but may be problematic with other cell types, and it can be difficult 
to load the cell while retaining the integrity of the compartments in 
Figure 6. Regulation of the p62 protein during autophagy. (A) The level of 
p62 during starvation. Atg5+/+ and Atg5-/- MEFs were cultured in DMEM 
without amino acids and serum for the indicated times, and then subjected to 
immunoblot analysis using anti-p62 antibody (Progen Biotechnik). This figure 
was previously published in reference 33, and is reproduced by permission 
of Landes Bioscience, copyright 2007. (B) The level of p62 in the brain of 
neural-cell specific Atg5 knockout mice. This image was generously provided 
by Dr. Taichi Hara (Tokyo Medical and Dental University).
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the post-nuclear supernatant (Tooze S, unpublished 
results). General points of caution to be addressed with 
regard to live cell imaging relate to photo-bleaching of 
the fluorophore, cell injury due to repetitive imaging, 
autofluorescence in tissues containing lipofuscin, and 
the pH sensitivity of the fluorophore.
6. Turnover of autophagic compartments. 
Inhibitors of autophagic sequestration (e.g., amino 
acids, 3-MA or wortmannin) can be used to monitor 
the disappearance of autophagic elements (phago-
phores, autophagosomes, autolysosomes) to estimate 
their half-life by electron microscopy morphometry/
stereology. The turnover of the autophagosome or the 
autolysosome will be differentially affected if fusion 
or intralysosomal degradation is inhibited.131-134 The 
duration of such experiments is usually only a few 
hours; therefore, long-term side effects or declining 
effectiveness of the inhibitors can be avoided. It should 
be noted that fluorescence microscopy has also been used to monitor 
the half-life of autophagosomes, monitoring GFP-LC3 in the pres-
ence and absence of bafilomycin A1 or following GFP-LC3 after 
starvation and recovery in amino acid-rich medium.107
Cautionary notes: The inhibitory effect must be strong and the 
efficiency of the inhibitor needs to be tested under the experimental 
conditions to be employed. Cycloheximide is frequently used as an 
autophagy inhibitor, but this is problematic because of the many 
potential indirect effects. For example, cycloheximide decreases the 
efficiency of protein degradation in several cell types  (Cuervo AM, 
personal communication). In addition, at high concentrations (in 
the millimolar range) cycloheximide inhibits complex I of the mito-
chondrial respiratory chain,135 but this is not a problem, at least in 
hepatocytes, at low concentrations (10–20 µM) that are sufficient to 
prevent protein synthesis (Meijer AJ, personal communication).
7. Autophagosome-lysosome colocalization and dequenching 
assay. Another method to demonstrate the convergence of the 
autophagic pathway with a functional degradative compartment is to 
incubate cells with the bovine serum albumin derivative de-quenched 
(DQ)-BSA that has been labeled with the red-fluorescent BODIPY 
TR-X dye; this conjugate will accumulate in lysosomes. The labeling 
of DQ-BSA is so extensive that the fluorophore is self-quenched. 
Proteolysis of this compound results in de-quenching and the 
release of brightly fluorescent fragments. Thus, the use of DQ-BSA 
is useful for detecting intracellular proteolytic activity as a measure 
of a functional lysosome (Colombo MI, personal communication). 
Furthermore, DQ-BSA labeling can be combined with GFP-LC3 to 
monitor colocalization and thus visualize the convergence of autopha-
gosomes with a functional degradative compartment. This method 
can also be used to visualize fusion events in real time experiments 
by confocal microscopy (live cell imaging). Along similar lines, other 
approaches for monitoring convergence are to follow the colocaliza-
tion of RFP-LC3 and LysoSensor Green (Bains M, Heidenreich KA, 
personal communication) or tagged versions of LC3 and LAMP-1 
(Macleod K, personal communication) as a measure of the fusion of 
autophagosomes with lysosomes.
Cautionary notes: Some experiments require the use of inhibi-
tors (e.g., 3-MA or wortmannin) or overexpression of proteins (e.g., 
Rab7 dominant negative mutants) that may also affect the endocytic 
pathway or the delivery of DQ-BSA to lysosomes. In this case, the 
lysosomal compartment can be labeled with DQ-BSA overnight 
before treating the cells with the drugs or prior to the transfection.
8. Sequestration and processing assays in plants. The fluoro-
phore of the red fluorescent protein shows a relatively high stability 
under acidic pH conditions. Thus, chimeric RFP fusion proteins 
that are sequestered within autophagosomes and delivered to the 
plant vacuole can be easily detected by fluorescence microscopy. 
Furthermore, fusion proteins with some versions of RFP tend to 
form intracellular aggregates, allowing the development of a visible 
autophagic assay for plant cells.136 For example, fusion of cyto-
chrome b5 and the original (tetrameric) RFP generate an aggregated 
cargo protein that displays cytosolic puncta of red fluorescence and, 
following vacuolar delivery, diffuse staining throughout the vacuolar 
lumen. This system allows autophagy to be monitored through fluo-
rescence microscopy with minimum damage to intact plant cells. In 
addition, the size difference between the intact and processed cargo 
protein allows the quantification of autophagic degradation through 
the detection of RFP after separation of total protein by gel electro-
phoresis, similar to the GFP-Atg8/LC3 processing assay described 
above. As with other systems, autophagosome formation in plants 
can also be monitored through the use of fluorescent protein fusions 
to Atg8, and electron microscopy (Fig. 7).
In some systems, including fungi and plants, the size of the vacuole 
is sufficiently large such that fusion of the autophagosome results in 
the release of the inner vesicle into the organelle lumen; the resulting 
single-membrane vesicle is termed an autophagic body (Fig. 8). The 
accumulation of autophagic bodies can be detected by light micros-
copy in cells that lack vacuolar hydrolase activity (e.g., the pep4∆ 
yeast mutant) or in the presence of inhibitors that interfere with 
hydrolase activity (e.g., PMSF or concanamycin). Using Nomarski 
optics (differential interference contrast) it is easy to distinguish and 
quantify yeast vacuoles that lack autophagic bodies from those that 
have accumulated them, and the same is true for plants.     
Cautionary notes: Although the detection of vacuolar RFP can be 
applied to both plant cell lines and to intact plants, it is not practical 
to measure RFP fluorescence in intact plant leaves, due to the very 
high red fluorescence of chloroplasts.  Furthermore, different autoph-
agic induction conditions cause differences in protein synthesis 
Figure 7. Detection of macroautophagy in tobacco BY-2 cells. (A) Induction of autophago-
somes in tobacco BY-2 cells expressing YFP-NtAtg8 (shown in green for ease of visualiza-
tion) under conditions of nitrogen limitation (Induced). Arrowheads indicate autophago-
somes that can be seen as a bright green dot. No such structure was found in cells grown 
in normal culture medium (Control). Bar, 10 µm. N, nucleus; V, vacuole. (B) Ultrastructure 
of an autophagosome in a tobacco BY-2 cell cultured for 24 h without a nitrogen source. 
Bar, 200 µm. AP, autophagosome; P, plastid; CW, cell wall. This image was provided by 
Dr. Kiminori Toyooka (RIKEN Plant Science Center).
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rates; thus, special care should be taken to monitor the efficiency of 
autophagy by quantifying the intact and processed cargo proteins. 
With regard to autophagic body accumulation, it is difficult to quan-
tify their number and/or volume, although their presence or absence 
can be examined by light or electron microscopy. In addition, the 
accumulation of autophagic bodies requires the inhibition of vacu-
olar hydrolase activity. Therefore, to demonstrate turnover the assay 
must be performed either in the absence and presence of appropriate 
inhibitors or in a strain with a deletion in a gene encoding a vacuolar 
hydrolase(s). Otherwise, accumulation of autophagic bodies could 
instead indicate a defect in the lysis/degradation step of autophagy. 
Finally, this method is not well suited for systems other than plants 
or fungi because lysosomes are too small for detection by standard 
(i.e., non-fluorescence) light microscopy, and fusion with autophago-
somes does not generate autophagic bodies (Fig. 8).
9. Tandem RFP-GFP fluorescence microscopy. A new assay that 
can be used to monitor flux relies on the use of a tandem monomeric 
RFP-GFP-tagged LC3 (tfLC3; Fig. 9).116 The GFP signal is sensitive 
to the acidic and/or proteolytic conditions of the lysosome lumen, 
whereas mRFP is more stable. Therefore, co-localization of both 
GFP and RFP fluorescence indicates a compartment that has not 
fused with a lysosome, such as the phagophore or an autophagosome. 
In contrast, an mRFP signal without GFP corresponds to an amphi-
some or autolysosome. Other fluorophores such as mCherry are also 
suitable instead of mRFP.73 One of the major advantages of this 
method is that it enables simultaneous estimation of both the induc-
tion of autophagy and flux through autophagic compartments in 
essentially native conditions, without requiring any drug treatment.
Cautionary notes: This is a new assay that has not been tested 
in a wide range of cell types. Accordingly, the sensitivity and the 
specificity of the method must be verified independently until this 
method has been tested more extensively.
10. Tissue fractionation. The study of autophagy in the organs of 
larger animals, in large numbers of organisms with very similar char-
acteristics, or in tissue culture cells provides an opportunity to use 
tissue fractionation techniques as has been possible with glucagon-
induced autophagy in rat liver.137-141 For the purpose of this 
section, it is important to clarify some of the terms used to identify 
components of the autophagic system.6 “Primary lysosomes” refer to 
Figure 9. The GFP and mRFP signals of tandem fluorescent LC3 (tfLC3, mRFP-
GFP-LC3) show different localization patterns. HeLa cells were cotransfected 
with plasmids expressing either tfLC3 or LAMP-1-CFP. Twenty-four hours after 
the transfection, the cells were starved in Hanks’ solution for 2 hours, fixed 
and analyzed by microscopy. The lower panels are a higher magnification 
of the upper panels. Bar, 10 µm in the upper panels and 2 µm in the lower 
panels. Arrows in the lower panels point to (or mark the location of) typical 
examples of colocalized signals of mRFP and LAMP-1. Arrowheads point to 
(or mark the location of) typical examples of colocalized particles of GFP and 
mRFP signals. This figure was previously published in reference 116, and is 
reproduced by permission of Landes Bioscience, copyright 2007.
Figure 8. Schematic drawing showing the formation of an autophagic body 
in plants and fungi. The large size of the plant and fungal vacuole relative 
to autophagosomes allows the release of the single-membrane autophagic 
body within the vacuole lumen. In cells that lack vacuolar hydrolase activity, 
or in the presence of inhibitors that block hydrolase activity, intact autopha-
gic bodies accumulate within the vacuole lumen and can be detected by light 
microscopy. The lysosome of most higher eukaryotes is too small to allow the 
release of an autophagic body.
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small vesicles containing acid hydrolases that have not participated 
in a previous digestive process, whereas “secondary lysosomes” are 
somewhat larger particles containing hydrolases and, in the case of 
late secondary lysosomes/telolysosomes, residues of previous diges-
tions. “Autophagosomes” contain cytoplasmic components but no 
hydrolases, and finally, “autolysosomes” or “autophagolysosomes” 
result from the fusion of autophagosomes with primary or secondary 
lysosomes. It has been shown that with proper homogenization tech-
niques,142 populations of particles making up the autophagic process 
in cells (autophagosomes, autolysosomes and telolysosomes) are 
present in tissue homogenates and are randomly distributed.139,143 
Because of their sizes (smaller than nuclei but larger than membrane 
fragments (microsomes)), differential centrifugation can be used 
to obtain a subcellular fraction enriched in mitochondria and 
organelles of the autophagic-lysosomal system (usually the classical 
Mitochondrial Fraction + Light Mitochondrial Fraction [M+L 
Fraction]; the L Fraction contains the highest activity for lysosomal 
enzymes, but the main component is still mitochondria), which can 
then be subjected to discontinuous density gradient centrifugation 
to separate autophagosomes, autolysosomes and lysosomes.143-145 
Any part of such a fraction can be considered to be a representative 
sample of tissue constituents and used in quantitative biochemical, 
centrifugational and morphological studies of autophagic particle 
populations. The data obtained can be further evaluated using 
sophisticated statistical analysis.
The simplest studies of the autophagic process take advantage of 
sequestered marker enzymes, changes in location of these enzymes, 
differences in particle/compartment size and differential sensitivity 
of particles of different sizes to mechanical and osmotic stress (acid 
hydrolases are found primarily in membrane-bound compartments 
and their latent activities cannot be measured unless these membranes 
are lysed). For example, autolysosomes/early secondary lysosomes are 
much larger than telolysosomes/late secondary lysosomes139 and the 
location of enzymes in the former can be detected by an increase in 
the release of these enzymes by osmotic shock or mechanical disrup-
tion.137,139,141 Such a change in enzyme accessibility can be used to 
follow the time course of an exogenously induced, or naturally occur-
ring, autophagic process.137,139,141
Quantitative localization of enzymatic activity (or any other 
marker) to specific cytoplasmic particle populations and changes 
in the location of such markers during autophagy can be carried 
out using rate sedimentation ultracentrifugation.143 Application 
of a centrifugal force to a sample of homogeneously distributed 
particles results in their migration at different speeds away from the 
axis of rotation, carrying their markers with them. This results in a 
distribution of marker activity, dependent on particle size and rela-
tive density, in fractions taken at different distances from the axis 
of rotation.143 These distributions can be used to determine which 
markers are in the same particles137,143 and whether or not the 
markers have moved to particles with different physical properties.139 
Similar results can be obtained with isopycnic centrifugation where 
particles enter a density gradient (sometimes made with sucrose but 
iso-osmotic media such as iodixanol, metrizamide and Nycodenz 
may be preferred as discussed below under Cautionary notes) and 
are centrifuged until they reach locations in the gradient where their 
densities are equal to those of the gradient.143
Particle populations in subcellular fractions evaluated with 
quantitative biochemical and centrifugational approaches can also 
be studied with quantitative morphological methods. Detailed 
morphological study of the particle populations involved in the 
autophagic process usually requires the use of electron microscopy. 
The thin sections required for such studies pose major sampling 
problems in both intact cells146 and subcellular fractions.143 With 
the latter, 2,000,000 sections can be obtained from each 0.1 ml of 
pellet volume, so any practical sample size is an infinitesimally small 
subsample of the total sample.143 However, through homogeniza-
tion and resuspension, complex and heterogeneous components of 
subcellular fractions become randomly distributed throughout the 
fraction volume. Therefore, as mentioned above, any aliquot of that 
volume can be considered a random sample of the whole volume. 
What is necessary is to conserve this property of subcellular frac-
tions in the generation of a specimen that can be examined with the 
electron microscope. This can be done with the use of a pressure 
filtration procedure147 to deposit the contents of an aliquot of frac-
tion volume on a filter, which is subsequently covered with a layer 
of red blood cells, processed for electron microscopy, embedded and 
sectioned.143 Because the direction of pressure is perpendicular to 
the plane of the filter, any section containing the full pellet thickness 
can be considered a random sample of the pellet volume. Because of 
the thinness of the sections, multiple sections of individual particles 
are possible so morphometric/stereological methods146 must be used 
to determine the volume occupied by a given class of particles, as 
well as  the size distribution and average size of the particle class. 
From this information the number of particles in a specific particle 
class can be calculated.148 If these data are obtained for all classes of 
particles in the autophagic system, the kinetics of particle interac-
tion can be evaluated.138 Examination of individual profiles gives 
information on the contents of different types of particles and their 
degree of degradation, as well as their enclosing membranes.137,139 
By combining the quantitative biochemical and morphological 
methods described above, it is possible to show that most of the popu-
lations of certain marker enzymes and specific cellular organelles have 
similar sedimentation properties, confirming the location of these 
enzymes.137,148 Furthermore, these approaches permit the identifica-
tion of compartments such as autophagosomes and autolysosomes in 
the same subcellular fraction without cytochemistry.139 
Cautionary notes: When isolating organelles from tissues and 
cells in culture it is essential to use disruption methods that do not 
alter the membrane of lysosomes and autophagosomes, compart-
ments that are particularly sensitive to some of those procedures. For 
example teflon/glass motor homogenization is suitable for tissues 
with abundant connective tissue, such as liver, but for circulating 
cells or cells in culture, disruption by nitrogen cavitation is the best 
method to preserve lysosomal membrane stability.149 During the 
isolation procedure it is essential to always use iso-osmotic solutions 
(e.g., 0.25 M sucrose) to avoid hypotonic or hypertonic disruption 
of the organelles. In that respect, because lysosomes are able to take 
up sucrose if it is present at high concentrations, the use of sucrose 
gradients for the isolation of intact lysosome-related organelles is 
strongly discouraged. Other density media such as Nycodenz, metri-
zamide and Percoll, cannot be transported inside lysosomes and 
subsequently are more suitable for their isolation. 
As with the isolation of any other intracellular organelle, it is 
essential to assess the purity of each preparation, as there is often 
considerable variability from experiment to experiment due to the 
many steps involved in the process. Correction for purity can be 
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done through calculation of recovery (percentage of the total activity 
present in the homogenate) and enrichment (multiplying by the 
specific activity in the homogenate) of enzymes or protein markers 
for those compartments (e.g., β-hexosaminidase is routinely used 
to assess lysosomal purity).149 Along these lines, it is essential to 
keep a balance sheet when using markers in biochemical studies 
of autophagy. This is necessary to insure that all marker activity is 
accounted for and that excessive damage to particles of interest has 
not occurred. Because of the time-consuming nature of quantitative 
morphological studies, such studies should not be carried out until 
simpler biochemical procedures have established the circumstances 
most likely to give meaningful morphometric/stereological results.
Finally, it is worthwhile noting that not all lysosomes are alike. 
For example, as noted above, there are differences among primary 
lysosomes, autolysosomes and telolysosomes. Furthermore, what 
we refer to as “lysosomes” are actually a very heterogeneous pool 
of organelles that simply fulfill five classical criteria, having a pH 
<5.6, cleaved cathepsins, the presence of LAMP proteins, a single 
membrane, and the absence of endosomal and recycling compart-
ment markers (e.g., the mannose-6-phosphate receptor or Rab5). 
But even applying those criteria we can separate lysosomes with clear 
differences in their proteome and other properties, and these distinct 
populations of lysosomes are likely to participate in different func-
tions in the cell.150
11. Analyses in vivo. Monitoring autophagic flux in vivo or 
in organs is one of the least developed areas at present, and ideal 
methods relative to the techniques possible with cell culture may 
not exist. One of the most useful methods is the analysis of GFP-
LC3/Atg8 (see Fluorescence microscopy above). The morphological 
detection of autophagic structures (e.g., autophagosomes) by fluo-
rescence or electron microscopy is one approach, although there are 
practical limits to the number of sections that can be prepared and 
analyzed. Extensive autophagy can result in obvious changes in cell 
morphology and the elimination of sufficient amounts of cytoplasm 
to cause cells to appear “clear.”151,152 Another useful approach is 
immunohistochemical staining, an important procedure considering 
the role of autophagy in protecting against certain neurodegenera-
tive diseases, and its potential roles in myopathies, heart disease and 
the response to ischemia/reperfusion, where samples may be limited 
to biopsies; however, this methodology has not received extensive 
evaluation, and does not lend itself well to dynamic assays. One 
method that has been used to monitor autophagy in myocytes is 
the detection of granular ubiquitin inclusions in the cytosol;46-48 
however, it is important to note that the presence of such inclusions 
may actually indicate decreased autophagy or autophagic flux. Along 
these lines, it is worth noting that immunodetection of LC3 is also 
possible using tissue sections.153 It is likely, however, that in vivo 
analyses will be relatively complex. For example, in skeletal muscle 
the induction of autophagy by starvation appears to occur more 
actively in very young animals (e.g., in 4 to 5 week old mice) than 
in more elderly organisms (e.g., in four month old mice) (Raben N, 
personal communication). 
Some biochemical assays may be used to at least provide indirect 
correlative data relating to autophagy, in particular when examining 
the role of autophagy in cell death. For example, cellular viability 
is related to high cathepsin B activity and low cathepsin D.154 
Therefore, the appearance of the opposite levels of activities may be 
one indication of the initiation of autophagy (lysosome)-dependent 
cell death. The question of “high” versus “low” activities can be 
determined by comparison to the same tissue under control condi-
tions, or to a different tissue in the same organism, depending on 
the specific question. Finally, certain molecular biology analyses are 
also possible, such as the detection of some cytokeratins that appear 
under autophagic conditions.152,155
With regard to living animals, a minimally invasive method that 
may be used even in humans is to measure the arterio-venous amino 
acid exchange rate in the peripheral tissues as a measure of post-
absorptive protein catabolism. In humans, the insulin- and amino 
acid-sensitive postabsorptive (autophagic) net protein catabolism in 
the peripheral (mostly skeletal muscle) tissue can be conveniently 
measured by determining the amino acid exchange rate across the 
lower extremities, as defined by the difference between the plasma 
amino acid concentrations in the femoral artery and femoral vein 
multiplied by the blood flow.156-158 Amino acid exchange studies 
have shown that the peripheral tissues take up amino acids during the 
post-prandial (fed) state and release amino acids in the postabsorp-
tive (fasted) state, i.e., in a state with relatively low plasma insulin 
and amino acid levels. This post-absorptive release of amino acids 
is strongly inhibited by infusion of insulin or by exogenous supply 
of amino acids suggesting that it is mainly mediated by a lysosomal/
autophagic mechanism of protein catabolism.156-163 
Finally, to obtain flux data it is necessary to include a time course 
parameter to follow changes in substrate accumulation. An example 
of this approach is seen with the study of Drosophila melanogaster blue 
cheese mutants, which accumulate ubiquitin-positive inclusions in a 
time-dependent manner.164
Cautionary notes: One caution in using approaches that monitor 
ubiquitinated aggregates is that the accumulation of ubiquitin may 
indicate a block in autophagy, inhibition of proteasomal degradation, 
or may correspond to structural changes in the substrate proteins that 
hinder their degradation. In addition, only cytosolic and not nuclear 
ubiquitin is subject to autophagic degeneration. When analyzing 
cathepsin D, it is advisable to use both western blots and activity 
assays; activity measurements alone can be misleading because 
procathepsin D is also active. In addition, it is important to realize 
that the level of mature cathepsin D is usually lower than expected 
in tissue that is undergoing autophagy; procathepsin D is matured 
in lysosomes, and extensive vacuolization resulting from autophagy 
interferes with trafficking of the enzyme through the endosome 
(Coto-Montes A, personal communication). Therefore, indirect 
measures of autophagy may be a higher ratio of procathepsin D to 
cathepsin D, or an alteration in the cathepsin B:cathepsin D activity 
ratio (potentially indicating the onset of autophagic cell death).
C. Methods Warranting Special Caution
1. Acidotropic dyes. One of the most frequently used methods 
for following autophagy is staining with acidotropic dyes such as 
monodansylcadaverine (MDC),165 acridine orange,166 LysoSensor 
Blue167 and LysoTracker Red.44
Cautionary notes: Although MDC was first described as a 
specific marker of autophagic vacuoles168 subsequent studies have 
suggested that this, and other acidotropic dyes, are not specific 
markers for early autophagosomes,79 but rather label later stages 
in the degradation process. For example, autophagosomes are not 
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acidic, and MDC staining can be seen in autophagy-defective 
mutants38 and in the absence of autophagy activation.169 MDC 
may also show confounding levels of background labeling unless 
narrow bandpass filters are used. On the other hand, in the presence 
of vinblastine, which blocks fusion with lysosomes, MDC labeling 
increases, suggesting that under these conditions MDC can label late 
stage autophagosomes.170 Along these lines, cells that overexpress 
a dominant negative version of Rab7 (the T22N mutant) show 
co-localization of this protein with MDC; in this case fusion with 
lysosomes is also blocked171 indicating that MDC does not just label 
lysosomes. Finally, MDC labeling is blocked by treatment with the 
autophagy inhibitors wortmannin or 3-MA.
Overall, staining with MDC or its derivative monodansylpen-
tane (MDH) is not, by itself, a sufficient method for monitoring 
autophagy. Similarly, LysoTracker Red and acridine orange are not 
ideal markers because they primarily detect lysosomes. For example, 
LysoTracker Red has been used to provide correlative data on 
autophagy in Drosophila melanogaster fat body cells (Fig. 10).43,44 
However, additional assays, such as GFP-Atg8/LC3 fluorescence or 
EM, should be used to substantiate results obtained with acidotropic 
dyes whenever possible. 
Some of the confusion regarding the interpretation of results with 
these dyes stems in part from the nomenclature in this field. Indeed, 
the discussion of acidotropic dyes points out why it is advisable to 
differentiate between the terms “autophagosome” and “autophagic 
vacuole,” although they are occasionally, and incorrectly, used inter-
changeably. The autophagosome is the sequestering compartment 
generated by the phagophore. The fusion of an autophagosome 
with an endosome or a lysosome generates an amphisome or an 
autolysosome, respectively. The early autophagosome is not an acidic 
compartment, whereas amphisomes and autolysosomes are acidic. 
Archaic names for these compartments are “initial autophagic vacuole 
(AVi),” “intermediate autophagic vacuole (AVi/d)” and “degradative 
autophagic vacuole (AVd),” respectively. Thus, acidotropic dyes 
can stain late autophagic vacuoles, but not the initial autophagic 
vacuole, the early autophagosome. With the above caveats in mind, 
the combined use of early and late markers of autophagy is highly 
encouraged, and when quantifying mammalian lysosomes, it is 
important to keep in mind that increases in both lysosome size and 
number are frequently observed. Finally, in order to avoid confu-
sion with the plant and fungal vacuole, the equivalent organelle to 
the lysosome, we recommend the use of the term “autophagosome” 
instead of “autophagic vacuole,” and the use of “autophagic compart-
ment” when the specific nature of the structure is not known.
2. Autophagy inhibitors and inducers. In many situations it 
is important to demonstrate an effect resulting from inhibition or 
stimulation of autophagy (see ref. 172 for a partial listing of regula-
tory compounds), and a few words of caution are worthwhile in 
this regard. Most chemical inhibitors of autophagy are not entirely 
specific, and it is preferable to analyze specific loss-of-function Atg 
mutants. However, it must be kept in mind that some apparently 
specific Atg gene products may have autophagy-independent roles 
(e.g., Atg5 in cell death). Therefore, the experimental conditions of 
inhibitor application and their side effects must be carefully consid-
ered. In addition, it must be emphasized once again that autophagy, 
as a multi-step process, can be inhibited at different stages. 
Sequestration inhibitors include for example, 3-MA, LY294002 
and wortmannin, which inhibit class I as well as class III phospha-
tidylinositol 3-kinases.132,173 The class I enzymes generate products 
that inhibit autophagic sequestration, whereas the class III products 
generally stimulate autophagic sequestration. The overall effect of 
these inhibitors is typically to block autophagy because the class III 
enzymes that are required to activate autophagy act downstream of 
the negative regulatory class I enzymes, although cell death may 
ensue in cell types that are dependent upon high levels of protein 
kinase B for survival. Although ineffective in isolated hepatocytes,174 
cycloheximide is a well established inhibitor of sequestration in 
vivo,131,133,134,175-181 and in certain cell types in vitro,182 and it has 
been utilized to investigate the dynamic nature of the regression of 
various autophagic elements.132-134,176-179 The mechanism of action 
of cycloheximide in short term experiments is not clear, but it has no 
direct relation to the inhibition of protein synthesis.174
Most other inhibitory drugs act at post-sequestration steps. These 
types of agents have been used in many experiments to both inhibit 
endogenous protein degradation and to increase the number of 
autophagic compartments. They cause the accumulation of seques-
tered material in either autophagosomes or autolysosomes, or both, 
because they allow autophagic sequestration to proceed. The main 
categories of these types of inhibitors include the vinca alkaloids 
(e.g., vinblastine) and other microtubule poisons that inhibit fusion, 
inhibitors of lysosomal enzymes (e.g., leupeptin, pepstatin A and 
E64d), and compounds that elevate lysosomal pH (e.g., inhibitors 
of vacuolar-type ATPases such as bafilomycin A1, and weak base 
amines including ammonia, methyl- or propylamine, chloroquine, 
and Neutral Red, some of which slow down fusion). It is worth 
noting that lysosomal proteases fall into the three general groups 
(cysteine, aspartic acid and serine). Therefore, the fact that leupeptin, 
a serine and cysteine protease inhibitor, has little or no effect does not 
necessarily indicate that lysosomal degradation is not taking place; 
a combination of leupeptin, pepstatin and E64d may be a more 
effective treatment. 
Figure 10. LysoTracker Red stains lysosomes and can be used to monitor 
autophagy in Drosophila melanogaster. Live fat body tissues from Drosophila 
melanogaster were stained with LysoTracker Red (red) and Höechst 33342 
(blue) to stain the nucleus. Tissues were isolated from fed (left) or 3 h starved 
(right) animals. Bar, 25 µm. This figure was modified from data presented 
in reference 44, Dev Cell, 7, Scott RC, Schuldiner O, Neufeld TP, Role and 
regulation of starvation-induced autophagy in the Drosophila fat body, 
pp. 167–78, copyright 2004, with permission from Elsevier. 
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As with the phosphatidylinositol 3-kinase inhibitors, many of 
these autophagy compounds are not specific. For example, okadaic 
acid is a powerful inhibitor of type 1 (PP1) and type 2A (PP2A) 
protein phosphatases.183 Bafilomycin A1 and other compounds 
that raise the lysosomal pH may have indirect effects on any acidi-
fied compartments. Thus, although these various agents can inhibit 
different steps of the autophagic pathway, their potential side effects 
must be considered in interpretation of the secondary consequences 
of autophagy inhibition, especially in long-term studies. For example, 
lysosomotropic compounds can increase the rate of autophagosome 
formation by inhibiting TORC1 (Høyer-Hansen M, unpublished 
observation). Along these lines, chloroquine treatment may cause 
an apparent increase in the formation of autophagosomes possibly 
by blocking fusion with the lysosome (Dorsey FC, Cleveland JL, 
personal communication). Furthermore, in addition to causing 
the accumulation of autophagic compartments, many of these 
drugs seem to be stimulators of sequestration in many cell types, 
especially in vivo.78,131,177,182,184-189 Although it is clear why these 
drugs cause the accumulation of autophagic compartments, it is not 
known why they stimulate sequestration. One possibility, at least for 
hepatocytes, is that the inhibition of protein degradation reduces 
the intracellular amino acid pool, which in turn upregulates seques-
tration. A time-course study of the changes in both the intra- and 
extracellular fractions may provide accurate information regarding 
amino acid metabolism. For these various reasons, it is important to 
include appropriate controls; along these lines, rapamycin or amino 
acid deprivation can be utilized as positive controls for inducing 
autophagy. In many cell types, however, the induction of autophagy 
by rapamycin is relatively slow, allowing more time for indirect 
effects. Finally, it has recently been shown that a specialized class of 
compounds with α, β-unsaturated ketone structure tends to induce 
autophagic cell death, accompanied by changes in mitochondrial 
morphology.190 Due to the potential pleiotropic effects of various 
drug treatments, it is incumbent upon the researcher to demonstrate 
that autophagy is indeed inhibited, by using the methodologies 
described herein.
The use of gene deletions (e.g., in primary or immortalized 
Atg-/- MEFs,38 or in vivo using transgenic knockout models191,192 
including Cre-lox based “conditional” knockouts74,75) or functional 
knockdowns (e.g., with RNAi) is the preferred approach when 
possible because these methods allow a more direct assessment of the 
resulting phenotype. In certain contexts, it is advisable when using a 
knockout or knockdown approach to examine multiple autophagy-
related genes to exclude the possibility that the phenotype observed is 
due to effects on a non-autophagic function(s) of the corresponding 
protein, especially when examining the possibility of autophagic 
cell death (in contrast, if examining whether perturbation induces 
clearance of a substrate via autophagy, a single Atg gene knockout is 
probably sufficient). This is particularly the case in evaluating Beclin 
1, which interacts with anti-apoptotic Bcl-2 family proteins,193 or 
when low levels of a target are sufficient for maintaining autophagy 
as is the case with Atg5.111 Along these lines, and as stated above 
for the use of inhibitors, when employing a knockout or especially 
a knockdown approach, it is again incumbent upon the researcher 
to demonstrate that autophagy is actually inhibited, by using the 
methodologies described herein. Finally, we note that the long-term 
secondary consequences of gene knockouts or knockdowns are 
likely much more complex than the immediate effects of the actual 
autophagy inhibition. To overcome this concern, tetracycline-regu-
lated reversible Atg5 knockout cells might be useful.111 Another 
strategy to specifically interfere with autophagy is to use dominant 
negative inhibitors. Delivery of these agents by transient transfec-
tion, adenovirus, or TAT-mediated protein transduction offers the 
possibility of their use in cell culture or in vivo.194 However, since 
autophagy is an essential metabolic process for many cell types and 
tissues, loss of viability due to autophagy inhibition always has to be 
a concern when analyzing cell death-unrelated questions.
There are fewer compounds that act as inducers of autophagy, but 
the initial characterization of this process was due in large part to the 
inducing effects of glucagon, which appears to act through indirect 
inhibition of mTOR via the activation of LKB1-AMPK.140,141,195 
Currently, the most commonly used and specific inducer of 
autophagy is rapamycin, which directly inhibits mTOR.84,196-198 
TOR-independent regulation can be achieved through lithium, 
sodium valproate and carbamezapine, compounds that lower the 
myo-inositol-1,4,5-triphosphate levels.199 Relatively little is known 
about direct regulation via the Atg proteins, but there is some indi-
cation that tamoxifen acts to induce autophagy by increasing the 
expression of Beclin 1.200 Finally, new screens have identified small 
molecules that induce autophagy independently of rapamycin, and 
allow the removal of misfolded or aggregate-prone proteins,201,202 
suggesting that they may prove useful in therapeutic applications.
3. Experimental systems. Throughout these guidelines we have 
noted that it is not possible to state explicit rules that can be applied 
to all experimental systems. For example, some techniques may not 
work in particular cell types or organisms. In some cases this must 
be empirically determined, which is one reason why it is impor-
tant to include appropriate controls. Differences may also be seen 
between in vivo or perfused organ studies and cell culture analyses. 
For example, insulin has no effect on proteolysis in suspended rat 
hepatocytes, in contrast to the result with perfused rat liver. The 
insulin effect reappears, however, when isolated hepatocytes are 
incubated in stationary dishes203,204 or are allowed to settle down on 
the matrix (Häussinger D, personal communication). The reason for 
this might be that autophagy regulation by insulin and some amino 
acids requires volume sensing via integrin-matrix interactions and 
also intact microtubules.205-207 Therefore, it is important to keep in 
mind that results from one particular system may not be generally 
applicable to others.
Conclusions and future perspectives
In conclusion, we suggest a set of recommended methods 
for monitoring macroautophagy in higher eukaryotes (Table 1). 
Importantly, investigators need to determine whether they are evalu-
ating autophagosome levels or autophagic flux. If the question being 
asked is whether a particular condition changes autophagic flux 
(i.e., the rate of delivery of autophagy substrates to lysosomes or the 
plant vacuole, followed by degradation), then assessment of steady 
state levels of autophagosomes (e.g., by counting GFP-LC3 puncta, 
monitoring the amount of LC3-II without examining turnover, or 
by electron microscopy) is not sufficient as an isolated approach. In 
this case it is also necessary to directly measure the flux of autopha-
gosomes and/or autophagy cargo (e.g., in wild-type cells compared 
to autophagy-deficient cells, the latter generated by treatment with 
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an autophagy inhibitor or resulting from Atg gene knockdowns). 
Collectively, we strongly recommend the use of multiple assays 
whenever possible, rather than relying on the results from a single 
method. 
As a final reminder, we stated at the beginning of this review 
that this set of guidelines is not meant to be a formulaic set of 
rules, because the appropriate assays depend in part on the question 
being asked and the system being used. Rather, these guidelines are 
presented primarily to emphasize key issues that need to be addressed 
such as the difference between measuring autophagy components, 
and flux or substrate clearance; they are not meant to constrain imag-
inative approaches to monitor autophagy. Hopefully, new methods 
for monitoring autophagy will continue to be developed, and new 
findings may alter our view of the current assays. For example, one 
area that shows promise is the use of nanoparticles as tools for moni-
toring autophagy,208 as they could be used in EM (e.g., providing 
contrast by using different sizes and shapes of nanoparticles) or 
to follow autophagic flux in living cells (e.g., relying on the stable 
fluorescence of quantum dots) allowing the tracking of autophago-
somes and amphisomes. Similar to the process of autophagy, this 
is a dynamic field, and we need to remain flexible in the standards 
we apply. 
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Glossary
Amphisome: Intermediate compartment formed by the fusion of 
an autophagosome with an endosome; this compartment has not yet 
fused with a lysosome (also referred to as an acidic late autophago-
some).
Autolysosome/autophagolysosome: A degradative compartment 
formed by the fusion of an autophagosome or amphisome with a 
primary lysosome or telolysosome. Upon completion of degradation, 
or when degradation has reached an end point, this compartment 
(again) becomes a telolysosome (also referred to as a residual body).
Autophagosome: A cytosolic membrane bound compartment 
typically denoted by a limiting double membrane. The early 
autophagosome in particular contains cytoplasmic components and 
organelles that are morphologically unchanged because the compart-
ment has not fused with a lysosome and lacks proteolytic enzymes.
Autophagy: A collection of processes typically involving degrada-
tive delivery of a portion of the cytoplasm to lysosomes or the plant 
or fungal vacuole that does not involve direct transport through the 
endocytic or vacuolar protein sorting, Vps, pathways.  
Chaperone-mediated autophagy (CMA): Import and degrada-
tion of soluble cytosolic proteins by chaperone-dependent, direct 
translocation across the lysosomal membrane.
Cytoplasm to vacuole targeting (Cvt): A biosynthetic pathway 
in fungi that transports resident hydrolases to the vacuole through a 
selective autophagy-related process.
Lysosome: A degradative organelle in higher eukaryotes that 
compartmentalizes a range of hydrolytic enzymes and maintains a 
highly acidic pH. A primary lysosome is a relatively small compart-
ment that has not yet participated in a degradation process, whereas 
secondary lysosomes are sites of present or past digestive activity. 
The secondary lysosomes include autolysosomes and telolysosomes. 
Autolysosomes/early secondary lysosomes are larger compartments 
actively engaged in digestion, whereas telolysosomes/late secondary 
lysosomes do not have significant digestive activity and contain 
residues of previous digestions. Both may contain material of either 
autophagic or heterophagic origin.
Macroautophagy: The largely nonspecific autophagic sequestra-
tion of cytoplasm into a double- or multiple-membrane-delimited 
compartment (an autophagosome) of nonlysosomal/vacuolar origin 
and its subsequent degradation by the lysosomal system. Note that 
certain proteins and organelles may be selectively degraded via a 
macroautophagy-related process, and conversely, some cytosolic 
components such as cytoskeletal elements are selectively excluded.
Microautophagy: Uptake and degradation of cytoplasm by 
protrusion, invagination or septation of the lysosome or vacuole 
membrane.
Mitophagy: The selective autophagic sequestration and degrada-
tion of mitochondria.
Pexophagy: A selective type of autophagy involving the seques-
tration and degradation of peroxisomes; can occur by a micro- or 
macroautophagic process.
Phagophore: Membrane cisterna that has been implicated in an 
initial event during formation of the autophagosome. Also referred 
to as the “isolation membrane.”
Phagophore assembly site (PAS): A perivacuolar compartment 
or location that is involved in the formation of Cvt vesicles and 
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autophagosomes in yeast. The PAS may supply membranes during 
the formation process or may be an organizing center where most of 
the autophagic machinery resides, at least transiently.
Phosphatidylinositol 3-kinase: A family of enzymes that add 
a phosphate group to the 3' hydroxyls on the inositol ring of 
phosphoinositides. The class III phosphatidylinositol 3-kinases are 
stimulatory for autophagy, whereas class I enzymes are inhibitory.
Programmed cell death (PCD): Regulated self-destruction of a 
cell. Type I is associated with apoptosis and is marked by cytoskeletal 
breakdown and condensation of cytoplasm and chromatin followed 
by fragmentation. Type II is associated with autophagy and is charac-
terized by the presence of enhanced levels of autophagosomes. Type 
III is marked by the absence of condensation, and does not involve 
the lysosomal system but rather is proteasome-dependent.
Vacuole: The fungal and plant equivalent of the lysosome; this 
organelle also carries out storage and osmoregulatory functions.
Xenophagy: The selective degradation of microbes (e.g., bacteria, 
fungi, parasites and/or viruses) through an autophagy-related 
mechanism. 
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